{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:21:40Z","timestamp":1789935700322,"version":"4.0.1"},"reference-count":36,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej22-0260","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T22:18:57Z","timestamp":1664921937000},"page":"149-159","source":"Crossref","is-referenced-by-count":8,"title":["Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin"],"prefix":"10.1507","volume":"70","author":[{"given":"Momoka","family":"Mizoguchi","sequence":"first","affiliation":[{"name":"Department of Life Science and Chemistry, Graduate School of Natural Science and Technology, Gifu University, Gifu 501-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takemori","sequence":"additional","affiliation":[{"name":"Department of Life Science and Chemistry, Graduate School of Natural Science and Technology, Gifu University, Gifu 501-1193, Japan"},{"name":"United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu 501-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saho","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Life Science and Chemistry, Graduate School of Natural Science and Technology, Gifu University, Gifu 501-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Taiko Pharmaceutical Co., Ltd., Osaka 550-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Asai","sequence":"additional","affiliation":[{"name":"Taiko Pharmaceutical Co., Ltd., Osaka 550-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Morino","sequence":"additional","affiliation":[{"name":"Taiko Pharmaceutical Co., Ltd., Osaka 550-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Miura","sequence":"additional","affiliation":[{"name":"Taiko Pharmaceutical Co., Ltd., Osaka 550-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism\/Department of Rheumatology and Clinical Nutrition, Gifu University Graduate School of Medicine, Gifu 501-1193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Taiko Pharmaceutical Co., Ltd., Osaka 550-0005, Japan"},{"name":"Strategic Global Partnership Cross-Innovation Initiative, Graduate School of Medicine, Osaka University Hospital, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Bailey CJ (2017) Metformin: historical overview. Diabetologia 60: 1566\u20131576.","DOI":"10.1007\/s00125-017-4318-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167\u20131174.","DOI":"10.1172\/JCI13505"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Bouchoucha M, Uzzan B, Cohen R (2011) Metformin and digestive disorders. Diabetes Metab 37: 90\u201396.","DOI":"10.1016\/j.diabet.2010.11.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, et al. (2012) The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull 35: 933\u2013937.","DOI":"10.1248\/bpb.35.933"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Takemori H, Hamamoto A, Isogawa K, Ito M, Takagi M, et al. (2020) Mouse model of metformin-induced diarrhea. BMJ Open Diabetes Res Care 8: e000898.","DOI":"10.1136\/bmjdrc-2019-000898"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Rivera-Ch\u00e1vez F, Meader BT, Akosman S, Koprivica V, Mekalanos JJ (2022) A potent inhibitor of the cystic fibrosis transmembrane conductance regulator blocks disease and morbidity due to toxigenic vibrio cholerae. Toxins (Basel) 14: 225.","DOI":"10.3390\/toxins14030225"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Thiagarajah JR, Verkman AS (2012) CFTR inhibitors for treating diarrheal disease. Clin Pharmacol Ther 92: 287\u2013290.","DOI":"10.1038\/clpt.2012.114"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, et al. (2019) Glucagon\u2013like peptide 1 (GLP-1). Mol Metab 30: 72\u2013130.","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, et al. (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24: 489\u2013494.","DOI":"10.2337\/diacare.24.3.489"},{"key":"10","doi-asserted-by":"crossref","first-page":"e93936","DOI":"10.1172\/jci.insight.93936","volume":"3","author":"E Bahne","year":"2018","unstructured":"10 Bahne E, Sun EWL, Young RL, Hansen M, Sonne DP, et al. (2018) Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 3: e93936.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Sun F, Yu K, Yang Z, Wu S, Zhang Y, et al. (2012) Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res 2012: 230624.","DOI":"10.1155\/2012\/230624"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, et al. (2021) Tirzepatide <i>versus<\/i> semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385: 503\u2013515.","DOI":"10.1056\/NEJMoa2107519"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 11: 202\u2013230.","DOI":"10.1900\/RDS.2014.11.202"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA (2017) Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab 19: 336\u2013347.","DOI":"10.1111\/dom.12824"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Grau-Bov\u00e9 C, Gonz\u00e1lez-Quilen C, Cantini G, Nardini P, Espina B, et al. (2022) GLP1 exerts paracrine activity in the intestinal lumen of human colon. Int J Mol Sci 23: 3523.","DOI":"10.3390\/ijms23073523"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Katoh Y, Takemori H, Lin XZ, Tamura M, Muraoka M, et al. (2006) Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling cascade. FEBS J 273: 2730\u20132748.","DOI":"10.1111\/j.1742-4658.2006.05291.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Matthews RP, McKnight GS (1996) Characterization of the cAMP response element of the cystic fibrosis transmembrane conductance regulator gene promoter. J Biol Chem 271: 31869\u201331877.","DOI":"10.1074\/jbc.271.50.31869"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Huang TT, Gu PP, Zheng T, Gou LS, Liu YW (2022) Piperine, as a TAS2R14 agonist, stimulates the secretion of glucagon-like peptide-1 in the human enteroendocrine cell line Caco-2. Food Funct 13: 242\u2013254.","DOI":"10.1039\/D1FO02932K"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Dulhanty AM, Riordan JR (1994) Phosphorylation by cAMP-dependent protein kinase causes a conformational change in the R domain of the cystic fibrosis transmembrane conductance regulator. Biochemistry 33: 4072\u20134079.","DOI":"10.1021\/bi00179a036"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, et al. (2010) Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 1: 56\u201359.","DOI":"10.1111\/j.2040-1124.2010.00010.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Honegger KJ, Capuano P, Winter C, Bacic D, Stange G, et al. (2006) Regulation of sodium-proton exchanger isoform 3 (NHE3) by PKA and exchange protein directly activated by cAMP (EPAC). Proc Natl Acad Sci U S A 103: 803\u2013808.","DOI":"10.1073\/pnas.0503562103"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, et al. (1998) Renal and intestinal absorptive defects in mice lacking the NHE3 Na+\/H+ exchanger. Nat Genet 19: 282\u2013285.","DOI":"10.1038\/969"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Han Y, Yun CC (2022) Metformin inhibits Na+\/H+ exchanger NHE3 resulting in intestinal water loss. Front Physiol 13: 867244.","DOI":"10.3389\/fphys.2022.867244"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Lin R, Murtazina R, Cha B, Chakraborty M, Sarker R, et al. (2011) D-glucose acts <i>via<\/i> sodium\/glucose cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na+\/H+ exchange regulatory factor 2-dependent process. Gastroenterology 140: 560\u2013571.","DOI":"10.1053\/j.gastro.2010.10.042"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Yang N, Dong YQ, Jia GX, Fan SM, Li SZ, et al. (2020) ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery. Biomed Pharmacother 132: 110835.","DOI":"10.1016\/j.biopha.2020.110835"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Shi AX, Zhou Y, Zhang XY, Zhao YS, Qin HY, et al. (2017) Irinotecan-induced bile acid malabsorption is associated with down-regulation of ileal Asbt (Slc10a2) in mice. Eur J Pharm Sci 102: 220\u2013229.","DOI":"10.1016\/j.ejps.2017.03.012"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Lee JH, Wen X, Cho H, Koo SH (2018) CREB\/CRTC2 controls GLP-1-dependent regulation of glucose homeostasis. FASEB J 32: 1566\u20131578.","DOI":"10.1096\/fj.201700845R"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Chen L, Yao X, Young A, McNulty J, Anderson D, et al. (2012) Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab 302: E68\u2013E76.","DOI":"10.1152\/ajpendo.00323.2011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, et al. (2018) Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 18: 3.","DOI":"10.1186\/s12876-017-0736-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Morino H, Ataka K, Ito M, Kuge T (2004) Wood creosote inhibits calcium mobilization in Guinea pig colonic smooth muscle. Biol Pharm Bull 27: 1046\u20131051.","DOI":"10.1248\/bpb.27.1046"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Yibcharoenporn C, Chusuth P, Jakakul C, Rungrotmongkol T, Chavasiri W, et al. (2019) Discovery of a novel chalcone derivative inhibiting CFTR chloride channel <i>via<\/i> AMPK activation and its anti-diarrheal application. J Pharmacol Sci 140: 273\u2013283.","DOI":"10.1016\/j.jphs.2019.07.012"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kongsuphol P, Cassidy D, Romeiras F, Schreiber R, Mehta A, et al. (2010) Metformin treatment of diabetes mellitus increases the risk for pancreatitis in patients bearing the CFTR-mutation S573C. Cell Physiol Biochem 25: 389\u2013396.","DOI":"10.1159\/000303043"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, et al. (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88: 801\u2013808.","DOI":"10.1038\/clpt.2010.184"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Zhao Q, Hong D, Zheng D, Xiao Y, Wu B (2014) Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug Des Devel Ther 8: 2283\u20132294.","DOI":"10.2147\/DDDT.S70945"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Kawalec P, Mikrut A, \u0141opuch S (2014) The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev 30: 269\u2013283.","DOI":"10.1002\/dmrr.2494"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Cravalho CKL, Meyers AG, Mabundo LS, Courville A, Yang S, et al. (2020) Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes. Diabetologia 63: 2194\u20132204.","DOI":"10.1007\/s00125-020-05236-y"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/2\/70_EJ22-0260\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:45:08Z","timestamp":1715316308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/2\/70_EJ22-0260\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej22-0260","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ22-0260"}}